Celldex Therapeutics (CLDX) CFO awarded 93,000 stock options grant
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Celldex Therapeutics, Inc. reported that its SVP and CFO, Martin Samuel Bates, received an incentive stock option grant covering 93,000 shares of common stock. The option has an exercise price of $34.09 per share and was awarded under the company’s 2021 Omnibus Equity Incentive Plan.
According to the vesting schedule, 25% of the options vest on June 25, 2027, with the remaining options vesting in equal quarterly installments over the following 12 quarters, and the option expires on June 25, 2036. After this grant, Bates holds 93,000 incentive stock options directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Martin Samuel Bates
Role
SVP AND CFO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Incentive Stock Option (right to buy) | 93,000 | $0.00 | -- |
Holdings After Transaction:
Incentive Stock Option (right to buy) — 93,000 shares (Direct, null)
Footnotes (1)
- Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. 25% vest on June 25, 2027 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.
Key Figures
Incentive stock options granted: 93,000 options
Exercise price: $34.09 per share
Options held after grant: 93,000 options
+3 more
6 metrics
Incentive stock options granted
93,000 options
Grant to SVP and CFO on June 25, 2026
Exercise price
$34.09 per share
Price to exercise the incentive stock options
Options held after grant
93,000 options
Total incentive stock options directly held following transaction
Initial vesting date
June 25, 2027
25% of options vest on this date
Remaining vesting period
12 quarters
Remaining 75% vests in equal quarterly installments
Expiration date
June 25, 2036
Option term end date
Key Terms
Incentive Stock Option, 2021 Omnibus Equity Incentive Plan, vesting, exercise price, +1 more
5 terms
Incentive Stock Option financial
"Incentive Stock Option (right to buy)"
An incentive stock option is a type of employee benefit that gives a worker the right to buy company shares at a fixed price, with special tax advantages if the employee holds the shares for a required period. Think of it as a coupon to buy future shares at today’s price that can result in lower tax on the gain. Investors care because ISOs can dilute share count, align staff incentives with the stock price, and affect company compensation costs and the timing of potential share sales.
2021 Omnibus Equity Incentive Plan financial
"Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan."
vesting financial
"25% vest on June 25, 2027 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters."
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
exercise price financial
"conversion_or_exercise_price: "34.0900""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: "2036-06-25T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
What insider transaction did Celldex Therapeutics (CLDX) report for Martin Samuel Bates?
Celldex reported that SVP and CFO Martin Samuel Bates received an incentive stock option grant for 93,000 shares. The options relate to Celldex common stock and are structured as a compensation award under the company’s 2021 Omnibus Equity Incentive Plan.
How many stock options did the Celldex (CLDX) CFO receive in this Form 4?
Martin Samuel Bates received an incentive stock option covering 93,000 underlying shares of Celldex common stock. This entire amount reflects a new grant, and following the transaction, he directly holds 93,000 incentive stock options as reported in the filing.
What is the exercise price of the Celldex (CLDX) CFO’s new stock options?
The incentive stock option granted to the Celldex SVP and CFO carries an exercise price of $34.09 per share. This price is the amount he must pay per share to convert the options into Celldex common stock when exercising.
When do the newly granted Celldex (CLDX) stock options start vesting?
The options begin vesting on June 25, 2027, when 25% of the grant vests. The remaining 75% then vest in equal quarterly installments over the subsequent 12 quarters, creating a multi-year vesting schedule tied to continued service.
When do the Celldex (CLDX) CFO’s newly granted options expire?
The incentive stock option grant to the Celldex SVP and CFO expires on June 25, 2036. After that expiration date, any unexercised portion of the 93,000 options can no longer be converted into Celldex common shares.
Under which plan were the Celldex (CLDX) CFO’s options granted?
The Form 4 states that the incentive stock option was granted pursuant to Celldex’s 2021 Omnibus Equity Incentive Plan. This plan provides the framework for equity-based awards like stock options to company executives and employees.